A Phase 2 interventional study of Bevacizumab (avastin) and FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) in Colorectal Neoplasms, sponsored by Pfizer. Completed at 83 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-19.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.
Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 12th largest by enrollment, is the only one that started in 2008, is one of 19 in phase 2, and was the 5th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Shanghai Pudong Hospital · Sites in China
Ages 18–75
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 8
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 102 across the 37 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 37 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
73 studies in Colorectal Neoplasms by Pfizer: 6 open now, 14 under way, 3 of them phase 3. Of 58 finished, 28 (48%) have results posted.
Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 20th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2008, is one of 21 in phase 2, and was the 19th registered.
Pfizer’s Colorectal Neoplasms studies by the year they started, since 1999.
5 of the studies testing Folfox protocol in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06475352UNICANCERDose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme | 2027-04 |
| NCT06106308Cardiff OncologyStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | 2027-04-16 |
| NCT07106034Shanghai Pudong HospitalStandard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial | 2027-07-31 |
| NCT06991465Neil KopekOrgan Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA) | 2027-09 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, from their registry updates:
Among Pfizer’s 73 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bevacizumab (avastin)
Drug: Bevacizumab (avastin) · Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
AG-013736 (axitinib)
Drug: AG-013736 (axitinib) · Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
AG-013736 (axitinib)
Drug: AG-013736 (axitinib) · Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
bevacizumab (avastin)
Drug: Bevacizumab (avastin) · Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Progression Free Survival (PFS)
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 week up to 130 weeks
Overall Survival (OS)
Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline until death or up to 1 year after the randomization of last participant
Percentage of Participants With Objective Response (OR)
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks
Duration of Response (DR)
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks
Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
Symptom severity score is comprised of average of 14 MDASI-D core items (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling and diarrhea) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last week; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome. Total average score range: 0 to 10.
Time frame: Baseline, Day 1 of cycles 2- 5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal
Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
Symptom Interference score is comprised of the average of 6 items on feeling or function from the MDASI-D core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last week; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome. Total average score range: 0 to 10.
Time frame: Baseline, Day 1 of cycle 2-5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal
| Milestone | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Started | 49 | 51 | 36 | 35 |
| Treated | 46 | 51 | 36 | 35 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 49 | 51 | 36 | 35 |
| Withdrew: Death | 31 | 31 | 21 | 23 |
| Withdrew: Lost to follow-up | 1 | 2 | 4 | 5 |
| Withdrew: Other | 13 | 15 | 10 | 7 |
| Withdrew: Objective progression or relapse | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Discontinued by sponsor | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 3 | 0 | 0 | 0 |
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Months | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 5.72 (4.50 to 7.42) | 6.87 (4.96 to 9.13) | 7.59 (5.62 to 11.07) | 6.44 (5.52 to 13.11) |
Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| Months | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Overall Survival (OS) | 12.9 (10.2 to 16.6) | 15.7 (12.1 to 23.0) | 17.1 (10.1 to 23.0) | 14.1 (9.0 to 16.4) |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
| Percentage of participants | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Percentage of Participants With Objective Response (OR) | 24.5 (13.3 to 38.9) | 23.5 (12.8 to 37.5) | 19.4 (8.2 to 36.0) | 20.0 (8.4 to 36.9) |
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Months | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Duration of Response (DR) | 7.52 (5.22 to NA) | 12.29 (7.39 to 12.84) | 10.15 (4.17 to 12.91) | 10.94 (4.53 to 12.68) |
Symptom severity score is comprised of average of 14 MDASI-D core items (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling and diarrhea) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last week; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome. Total average score range: 0 to 10.
| Units on a Scale | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Baseline (n=39,46,35,33) | 2.1 (1.6 to 2.6) | 1.8 (1.3 to 2.2) | 1.9 (1.3 to 2.5) | 2.0 (1.4 to 2.7) |
| Change at Cycle 2/Day 1 (n=35, 39, 34,28) | 0.6 (0.2 to 1.1) | 0.5 (-0.1 to 1.0) | 0.7 (0.2 to 1.2) | 0.0 (-0.4 to 0.5) |
| Change at Cycle 3/Day 1 (n=36,36,33,26) | 0.8 (0.2 to 1.4) | 0.2 (-0.3 to 0.6) | 0.3 (-0.4 to 1.0) | 0.2 (-0.3 to 0.7) |
| Change at Cycle 4/Day 1 (n=29,37,32,25) | 0.8 (0.0 to 1.5) | 0.0 (-0.4 to 0.5) | 0.5 (-0.2 to 1.1) | 0.5 (-0.1 to 1.1) |
| Change at Cycle 5/Day 1 (n=28,29,24,24) | 0.5 (0.0 to 1.1) | 0.1 (-0.4 to 0.7) | 0.9 (0.2 to 1.7) | 0.4 (-0.2 to 0.9) |
| Change at Cycle 7/Day 1 (n=26,31,22,20) | 0.7 (0.1 to 1.2) | 0.0 (-0.6 to 0.5) | 0.6 (0.1 to 1.1) | 0.2 (-0.5 to 0.9) |
| Change at Cycle 9/Day 1 (n=19,26,19,17) | 1.1 (0.3 to 1.9) | -0.2 (-0.7 to 0.2) | 0.6 (-0.1 to 1.3) | 0.8 (0.3 to 1.3) |
| Change at Cycle 11/Day 1 (n=15,24,16,15) | 1.0 (0.1 to 1.9) | 0.1 (-0.5 to 0.7) | 1.0 (0.2 to 1.8) | 0.1 (-0.8 to 1.1) |
| Change at Cycle 13/Day 1 (n=13,19,15,10) | 1.0 (-0.5 to 2.6) | 0.1 (-0.6 to 0.7) | 0.9 (0.2 to 1.6) | 0.8 (0.1 to 1.4) |
| Change at Cycle 15/Day 1 (n=7,17,12,8) | 0.8 (-1.6 to 3.3) | 0.2 (-0.3 to 0.7) | 0.5 (-0.4 to 1.3) | 1.0 (0.4 to 1.6) |
| Change at Cycle 17/Day 1 (n=6,11,11,7) | 2.0 (-0.9 to 5.0) | 0.4 (-0.3 to 1.0) | 0.9 (0.1 to 1.8) | 1.7 (0.7 to 2.7) |
| Change at Cycle 19/Day 1 (n=6,10,9,5) | 1.3 (-1.5 to 4.1) | 0.5 (-0.7 to 1.7) | 0.8 (-0.2 to 1.8) | 1.4 (0.7 to 2.2) |
| Change at Cycle 21/Day 1 (n=6,9,7,4) | 1.1 (-2.2 to 4.4) | 0.5 (-0.5 to 1.5) | 0.9 (-0.9 to 2.7) | 1.6 (0.3 to 2.8) |
| Change at Cycle 23/Day 1 (n=5,7,6,4) | 2.6 (0.3 to 4.8) | -0.3 (-0.9 to 0.3) | 0.4 (-1.4 to 2.3) | 1.0 (0.8 to 1.2) |
| Change at Cycle 25/Day 1 (n=5,7,6,3) | 2.2 (-1.2 to 5.6) | 0.1 (-1.2 to 1.4) | 0.2 (-2.0 to 2.3) | 1.0 (0.5 to 1.4) |
| Change at Cycle 27/Day 1 (n=2,7,3,3) | 2.3 (-20.8 to 25.5) | 0.4 (-1.4 to 2.3) | 0.3 (-5.4 to 5.9) | 1.1 (0.6 to 1.5) |
| Change at Cycle 29/Day 1 (n=2,5,2,3) | 2.8 (-25.8 to 31.4) | -0.2 (-1.3 to 0.9) | -0.8 (-1.7 to 0.1) | 0.9 (-0.3 to 2.1) |
| Change at Cycle 31/Day 1 (n=1,5,2,2) | 4.9 (NA to NA) | -0.4 (-1.2 to 0.3) | -0.3 (-5.7 to 5.2) | 0.9 (-1.4 to 3.2) |
| Change at Cycle 33/Day 1 (n=1,3,2,1) | 5.0 (NA to NA) | -0.6 (-3.2 to 2.0) | -0.8 (-7.6 to 6.1) | 0.5 (NA to NA) |
| Change at Cycle 35/Day 1 (n=0,4,1,1) | NA (NA to NA) | -0.4 (-1.5 to 0.7) | 0.4 (NA to NA) | 2.4 (NA to NA) |
| Change at Cycle 37/Day 1 (n=0,4,0,1) | NA (NA to NA) | -0.5 (-1.3 to 0.4) | NA (NA to NA) | 1.0 (NA to NA) |
| Change at Cycle 39/Day 1 (n=0,2,0,1) | NA (NA to NA) | -0.4 (-0.8 to 0.1) | NA (NA to NA) | 1.0 (NA to NA) |
| Change at Cycle 41/Day 1 (n=0,2,0,1) | NA (NA to NA) | -0.3 (-0.8 to 0.1) | NA (NA to NA) | 1.4 (NA to NA) |
| Change at Cycle 43/Day 1 (n=0,1,0,1) | NA (NA to NA) | -0.4 (NA to NA) | NA (NA to NA) | 2.0 (NA to NA) |
| Change at Cycle 45/Day 1 (n=0,0,0,1 ) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.2 (NA to NA) |
| Change at Cycle 47/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.4 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 49/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.5 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 51/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.4 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 53/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.4 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 55/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 57/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 59/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 61/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.2 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 63/Day 1 (n=0,0,0,0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 65/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.4 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at end of treatment (n=21,29,27,22) | 0.7 (-0.2 to 1.6) | 0.5 (-0.1 to 1.0) | 1.3 (0.4 to 2.1) | 0.9 (0.1 to 1.7) |
Symptom Interference score is comprised of the average of 6 items on feeling or function from the MDASI-D core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last week; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome. Total average score range: 0 to 10.
| Units on a Scale | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| Baseline (n=39,46,35,33) | 2.1 (1.4 to 2.8) | 1.7 (1.1 to 2.3) | 2.4 (1.6 to 3.2) | 2.8 (1.8 to 3.9) |
| Change at Cycle 2/Day 1 (n=35, 39, 34, 28) | 0.8 (0.0 to 1.5) | 0.9 (0.2 to 1.6) | 0.1 (-0.6 to 0.7) | -0.5 (-1.2 to 0.1) |
| Change at Cycle 3/Day 1 (n=36,36,33,26) | 1.3 (0.5 to 2.2) | 0.3 (-0.3 to 0.8) | 0.3 (-0.6 to 1.2) | -0.2 (-1.0 to 0.6) |
| Change at Cycle 4/Day 1 (n=29,37,32,25) | 0.8 (-0.1 to 1.7) | -0.2 (-0.9 to 0.4) | 0.2 (-0.6 to 1.1) | 0.5 (-0.2 to 1.3) |
| Change at Cycle 5/Day 1 (n=28,29,24,24) | 1.0 (0.3 to 1.6) | 0.4 (-0.7 to 1.4) | 0.8 (-0.4 to 2.0) | 0.3 (-0.6 to 1.2) |
| Change at Cycle 7/Day 1 (n=26,30,22,20) | 0.7 (-0.1 to 1.5) | 0.4 (-0.4 to 1.2) | 0.4 (-0.3 to 1.1) | 0.0 (-0.8 to 0.7) |
| Change at Cycle 9/Day 1 (n=18,25,19,17) | 1.1 (0.2 to 1.9) | 0.3 (-0.6 to 1.1) | 0.6 (-0.5 to 1.6) | 0.3 (-0.8 to 1.4) |
| Change at Cycle 11/Day 1 (n=15,24,16,15) | 1.0 (0.0 to 2.1) | 0.3 (-0.6 to 1.3) | 0.8 (0.0 to 1.6) | -0.2 (-1.6 to 1.2) |
| Change at Cycle 13/Day 1 (n=13,19,15,10) | 1.1 (-0.4 to 2.7) | 0.7 (-0.2 to 1.5) | 1.3 (0.4 to 2.2) | 0.7 (-0.7 to 2.1) |
| Change at Cycle 15/Day 1 (n=7,17,12,8) | 2.3 (0.8 to 3.8) | 0.9 (-0.3 to 2.0) | -0.1 (-1.4 to 1.3) | 1.3 (0.0 to 2.5) |
| Change at Cycle 17/Day 1 (n=6,11,11,7) | 2.4 (0.9 to 3.8) | 0.7 (-0.7 to 2.1) | 0.7 (-1.3 to 2.6) | 2.1 (-0.1 to 4.3) |
| Change at Cycle 19/Day 1 (n=6,10,9,5) | 2.1 (0.6 to 3.6) | 0.8 (-0.6 to 2.3) | 0.3 (-1.6 to 2.2) | 2.4 (1.2 to 3.7) |
| Change at Cycle 21/Day 1 (n=6,9,7,4) | 1.7 (-0.3 to 3.7) | 1.0 (-1.2 to 3.2) | 0.4 (-1.0 to 1.8) | 2.1 (0.8 to 3.4) |
| Change at Cycle 23/Day 1 (n=5,7,6,4) | 2.2 (0.0 to 4.4) | -0.3 (-1.3 to 0.8) | 0.9 (-1.7 to 3.4) | 1.4 (0.8 to 2.0) |
| Change at Cycle 25/Day 1 (n=5,7,6,3) | 1.6 (-0.9 to 4.1) | 0.5 (-2.0 to 3.0) | -0.6 (-2.7 to 1.5) | 1.4 (0.5 to 2.3) |
| Change at Cycle 27/Day 1 (n=2,7,3,3) | 1.6 (-16.4 to 19.6) | 0.9 (-2.1 to 4.0) | -1.6 (-5.7 to 2.4) | 1.3 (0.9 to 1.7) |
| Change at Cycle 29/Day 1 (n=2,5,2,3) | 3.2 (-26.5 to 32.8) | 0.0 (-2.3 to 2.2) | -1.3 (-15.0 to 12.5) | 1.3 (-0.4 to 3.0) |
| Change at Cycle 31/Day 1 (n=1,5,2,2) | 4.5 (NA to NA) | -0.5 (-2.1 to 1.0) | -0.1 (-26.6 to 26.4) | 1.2 (-3.1 to 5.4) |
| Change at Cycle 33/Day 1 (n=1,3,2,1) | 4.5 (NA to NA) | -0.2 (-4.4 to 3.9) | -0.8 (-29.3 to 27.8) | 0.3 (NA to NA) |
| Change at Cycle 35/Day 1 (n=0,4,1,1 ) | NA (NA to NA) | -0.3 (-1.9 to 1.2) | -1.2 (NA to NA) | 3.3 (NA to NA) |
| Change at Cycle 37/Day 1 (n=0,4,0,1) | NA (NA to NA) | -0.4 (-2.1 to 1.2) | NA (NA to NA) | 1.3 (NA to NA) |
| Change at Cycle 39/Day 1 (n=0,2,0,1) | NA (NA to NA) | -0.3 (-0.3 to -0.3) | NA (NA to NA) | 2.0 (NA to NA) |
| Change at Cycle 41/Day 1 (n=0,2,0,1) | NA (NA to NA) | -0.2 (-2.3 to 2.0) | NA (NA to NA) | 1.5 (NA to NA) |
| Change at Cycle 43/Day 1 (n=0,1,0,1) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | 1.8 (NA to NA) |
| Change at Cycle 45/Day 1 (n=0,0,0,1 ) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.5 (NA to NA) |
| Change at Cycle 47/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.2 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 49/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 51/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 53/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.2 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 55/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.3 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 57/Day 1 (n=0,1,0,0) | NA (NA to NA) | 0.0 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 59/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.2 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 61/Day 1 (n=0,1,0,0) | NA (NA to NA) | 0.0 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 63/Day 1 (n=0,0,0,0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at Cycle 65/Day 1 (n=0,1,0,0) | NA (NA to NA) | -0.2 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Change at end of treatment (n=21,29,26,21) | 1.3 (0.5 to 2.1) | 1.0 (0.3 to 1.6) | 1.5 (0.2 to 2.8) | 1.2 (0.0 to 2.4) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + FOLFIRI | — | 17/46 (37%) | 45/46 (97.8%) |
| Bevacizumab + FOLFIRI | — | 9/51 (17.6%) | 51/51 (100%) |
| Axitinib + FOLFOX | — | 11/36 (30.6%) | 35/36 (97.2%) |
| Bevacizumab + FOLFOX | — | 5/35 (14.3%) | 33/35 (94.3%) |
| Event | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 4/46 | 0/51 | 1/36 | 0/35 |
| DiarrhoeaGastrointestinal disorders | 3/46 | 2/51 | 0/36 | 1/35 |
| Disease progressionGeneral disorders | 2/46 | 3/51 | 0/36 | 0/35 |
| Abdominal painGastrointestinal disorders | 2/46 | 0/51 | 1/36 | 0/35 |
| NauseaGastrointestinal disorders | 2/46 | 1/51 | 0/36 | 0/35 |
| AstheniaGeneral disorders | 2/46 | 0/51 | 0/36 | 0/35 |
| FatigueGeneral disorders | 2/46 | 0/51 | 1/36 | 0/35 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/46 | 0/51 | 0/36 | 0/35 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/46 | 1/51 | 0/36 | 0/35 |
| VomitingGastrointestinal disorders | 1/46 | 2/51 | 1/36 | 0/35 |
| Event | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 32/46 | 25/51 | 15/36 | 11/35 |
| HypertensionVascular disorders | 17/46 | 8/51 | 24/36 | 6/35 |
| NauseaGastrointestinal disorders | 27/46 | 30/51 | 18/36 | 16/35 |
| NeutropeniaBlood and lymphatic system disorders | 20/46 | 27/51 | 20/36 | 10/35 |
| Decreased appetiteMetabolism and nutrition disorders | 24/46 | 16/51 | 13/36 | 7/35 |
| VomitingGastrointestinal disorders | 22/46 | 18/51 | 12/36 | 3/35 |
| Neuropathy peripheralNervous system disorders | 3/46 | 4/51 | 7/36 | 16/35 |
| FatigueGeneral disorders | 21/46 | 18/51 | 12/36 | 9/35 |
| ConstipationGastrointestinal disorders | 7/46 | 16/51 | 3/36 | 10/35 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 11/46 | 15/51 | 4/36 | 5/35 |
| Age, Customized(Participants) | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX | Total |
|---|---|---|---|---|---|
| 18 to 44 years | 5 | 6 | 3 | 1 | 15 |
| 45 to 64 years | 30 | 34 | 21 | 22 | 107 |
| Greater than and equal to 65 years | 14 | 11 | 12 | 12 | 49 |
| Sex: Female, Male(Participants) | Axitinib + FOLFIRI | Bevacizumab + FOLFIRI | Axitinib + FOLFOX | Bevacizumab + FOLFOX | Total |
|---|---|---|---|---|---|
| Female | 18 | 24 | 20 | 11 | 73 |
| Male | 31 | 27 | 16 | 24 | 98 |
The record gives a start of Mar 2008, a primary completion of Mar 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Axitinib · Folfox protocol